Inversion kinetics of some E / Z 3-(benzylidene)-2-oxo-indoline derivatives and their in silico CDK2 docking studies.

The structure-based design of some CDK2 inhibitors with a 3-(benzylidene)indolin-2-one scaffold as potential anticancer agents was realized. Target compounds were obtained as E / Z mixtures and were resolved to corresponding E - and Z -diastereomers. In silico studies using MOE 2019.01 software revealed better docking on the targeted enzyme for the Z -diastereomer compared to the E -one. A time-dependent kinetic isomerization study was carried out for the inversion of E / Z diastereomers in DMSO-d 6 at room temperature, and were found to obey the first order kinetic reactions. Furthermore, a determination of the kinetic inter-conversion rate order by graphical analysis method and calculation of the rate constant and half-life of this kinetic process were carried out. For the prediction of the stability of the diastereomer(s), a good multiple regression equation was generated between the reaction rates of isomerization and some QM parameters with significant p value.